AMPH Amphastar Pharmaceuticals, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$23.62

Period return

+4.08 (+20.88%)

Volume

1.5M

2026-09-18O $23.69 H $23.99 L $23.51 C $23.62MA5 $23.79MA20 $22.97MA60 $21.02MA120 $20.56

6M · 127 barsYahoo Finance · USD2026-03-19 → 2026-09-18

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 06.Highlast month
Next earnings date
EPS 컨센서스 0.67 · 매출 컨센서스 1.8억. 발표 후 실제치와 비교하세요.
2026. 06. 30.Medium3 months ago
Q2 2026 earnings
EPS 0.67 · 매출 1.8억. 세부 수치와 가이던스는 원문에서 확인하세요.
2026. 05. 14.MediumHOLD4 months ago
Wells Fargo: Equal-Weight
US analyst rating / recommendation change.
2026. 05. 12.LowHOLD4 months ago
Piper Sandler: Neutral
US analyst rating / recommendation change.
2026. 05. 08.MediumHOLD4 months ago
Needham: Hold
US analyst rating / recommendation change.
2026. 04. 22.MediumHOLD5 months ago
Jefferies: Hold
US analyst rating / recommendation change.
2026. 04. 08.LowHOLD5 months ago
Barclays: Equal-Weight
US analyst rating / recommendation change.
2026. 03. 31.Medium6 months ago
Q1 2026 earnings
EPS 0.14 · 매출 1.7억. 세부 수치와 가이던스는 원문에서 확인하세요.
2026. 02. 28.LowBUY7 months ago
Wells Fargo: Overweight
US analyst rating / recommendation change.
2026. 02. 27.LowBUY7 months ago
Needham: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 06.	After market close (AMC)	$0.67	—	—	$180.34M	—	Scheduled
FY2026 Q2	2026. 06. 30.	Time TBD	—	$0.67	—	—	$183.9M	Reported
FY2026 Q1	2026. 03. 31.	Time TBD	—	$0.14	—	—	$171.17M	Reported
FY2025 Q4	2025. 12. 31.	Time TBD	—	—	—	—	$183.11M	Reported

Research actions

Consensus PT $22.5 · 6 analysts

Research tab →

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 14.	Wells Fargo	—	Downgrade	Overweight → Equal-Weight	—	Wells Fargo: Overweight → Equal-Weight
2026. 05. 12.	Piper Sandler	—	Maintain	Neutral → Neutral	—	Piper Sandler: Neutral
2026. 05. 08.	Needham	—	Downgrade	Buy → Hold	—	Needham: Buy → Hold
2026. 04. 22.	Jefferies	—	Downgrade	Buy → Hold	—	Jefferies: Buy → Hold
2026. 04. 08.	Barclays	—	Maintain	Equal-Weight → Equal-Weight	—	Barclays: Equal-Weight
2026. 02. 28.	Wells Fargo	—	Maintain	Overweight → Overweight	—	Wells Fargo: Overweight

Key stats

As of FY2021Q3 · Source: SEC/DART + price data

Market cap$1B

Shares out.43M

PER12.77x

EPS (TTM)$1.85

PBR2.34x

BPS$10.11

Dividend/share—

Dividend yield—

Consensus—

Price target$22.50-4.7%

Target range$20.00 ~ $30.00· 6 analysts

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

No holdings data to show.

Company info

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
HQ: Rancho Cucamonga, CA, United States
Fiscal year end: —
Employees: 1,976
IPO date: —

View details →

Top news

Stored first · Google News · Yahoo Finance (English)

Quarter

Date

Time

EPS est.

EPS actual

Surprise

Rev. est.

Rev. actual

Status

—

2026. 08. 06.

After market close (AMC)

$0.67

—

$180.34M

—

Scheduled

FY2026 Q2

2026. 06. 30.

Time TBD

—

$0.67

—

$183.9M

Reported

FY2026 Q1

2026. 03. 31.

Time TBD

—

$0.14

—

$171.17M

Reported

FY2025 Q4

2025. 12. 31.

Time TBD

—

$183.11M

Reported

Date

Firm

Analyst

Action

Rating change

Price target

Report

2026. 05. 14.

Wells Fargo

—

Downgrade

Overweight → Equal-Weight

—

Wells Fargo: Overweight → Equal-Weight

2026. 05. 12.

Piper Sandler

—

Maintain

Neutral → Neutral

—

Piper Sandler: Neutral

2026. 05. 08.

Needham

—

Downgrade

Buy → Hold

—

Needham: Buy → Hold

2026. 04. 22.

Jefferies

—

Downgrade

Buy → Hold

—

Jefferies: Buy → Hold

2026. 04. 08.

Barclays

—

Maintain

Equal-Weight → Equal-Weight

—

Barclays: Equal-Weight

2026. 02. 28.

Wells Fargo

—

Maintain

Overweight → Overweight

—

Wells Fargo: Overweight